The ISSCR: who are we and where are we going?

ISSCR, Stanford Institute of Stem Cell Biology and Regenerative Medicine, USA.
Cell stem cell (Impact Factor: 22.27). 09/2009; 5(2):151-3. DOI: 10.1016/j.stem.2009.07.013
Source: PubMed
1 Read
  • Source
    • "The ISSCR Task Force on Unproven Stem Cell Treatments (hereafter the Task Force) was convened by the 2009–2010 President of the ISSCR, Dr. Irving Weissman, to formulate recommendations for the development of a web-based resource for patients, their advocates, clinicians, and associations in evaluating claims of benefit from advertised stem cell treatments. In particular, the Task Force was asked to propose a process for listing clinics or programs and whether they meet what the ISSCR deems to be minimum standards of assessing safety and efficacy and to define criteria to systematically evaluate clinics or programs for inclusion on such a list (Weissman, 2009). The members of the Task Force are listed in Table S1. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A report by the International Society for Stem Cell Research (ISSCR)'s Task Force on Unproven Stem Cell Treatments outlines development of resources for patients, their families, and physicians seeking information on stem cell treatments.
    Cell stem cell 07/2010; 7(1):43-9. DOI:10.1016/j.stem.2010.06.001 · 22.27 Impact Factor
  • Source
    • "Although, as we discuss later, NIH's informed consent standard is in some ways more restrictive than others, the consent requirement itself was hardly surprising or objectionable. What is surprising, given its departure from prevailing norms (National Research Council 2005; ISSCR 2006)—and is, to many hESC advocates, disappointing (Connolly 2009; NYSCF 2009; New York Times 2009; Weissman 2009)—is NIH's decision to continue the Bush policy of only funding research on lines derived from embryos that were created, but no longer needed, for reproductive purposes—i.e., " spare IVF embryos. " Lines derived from all other sources, including parthenogenesis, SCNT, and IVF embryos created for research, remain ineligible. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many assumed that the Obama administration would usher in a sea change from the previous administration by expanding NIH support for human embryonic stem cell (hESC) research and reducing the patchwork of state and federal regulations that currently governs it. This article examines the extent to which NIH's new Guidelines are likely to accomplish these goals.
    Kennedy Institute of Ethics journal 09/2009; 19(3):289-307. DOI:10.1353/ken.0.0289 · 1.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This report presents the recommendations to the ISSCR leadership from the industry panel session at the 2009 annual conference. The seven recommendations address core issues essential for the promotion of stem cell and regenerative medicine translation and commercialization.
    Cell stem cell 10/2009; 5(4):379-84. DOI:10.1016/j.stem.2009.09.006 · 22.27 Impact Factor
Show more


1 Read
Available from

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.